일리노이의 루푸스 임상 시험
루푸스 관련 연구 14개가 일리노이 내 여러 지역에서 참여자를 모집하고 있습니다.
일리노이의 도시
공식 연구 텍스트(영어)
A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus
- Research Site, Willowbrook
피험자 모집 중3상
18세 ~ 70세 · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT07430306A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous Injections of ABBV-519 in Adult Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)
- Advanced Quality Medical Research /ID# 279147, Orland Park
피험자 모집 중1상
18세 ~ 75세 · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT07607964A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
- Willow Rheumatology and Wellness PLLC, Willowbrook
피험자 모집 중3상
18세 ~ 75세 · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT07438496A Phase IIa Study of ICG318 CAR-T in Refractory Systemic Lupus Erythematosus With or Without Lupus Nephritis
- University of Chicago, Chicago
피험자 모집 중2상
16세 ~ 70세 · 모든 성별 · 2026. 9. 17. 업데이트됨 · NCT07328581A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
- The University of Chicago Medical Center, Chicago
피험자 모집 중1상
18세 ~ 74세 · 모든 성별 · 2026. 9. 10. 업데이트됨 · NCT07085104An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
- Research Site, Chicago
- Research Site, Chicago
피험자 모집 중3상
5세 ~ 17세 · 모든 성별 · 2026. 9. 10. 업데이트됨 · NCT05835310A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE
- Research Site, Chicago
피험자 모집 중1/2상
18세 ~ 70세 · 모든 성별 · 2026. 9. 10. 업데이트됨 · NCT06897930A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
- Sl0044 50699, Chicago
- Sl0044 50717, Willowbrook
피험자 모집 중3상
16세 이상 · 모든 성별 · 2026. 9. 4. 업데이트됨 · NCT06617325A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants
- Willow Rheumatology & Wellness, Willowbrook
피험자 모집 중관찰 연구
16세 이상 · 모든 성별 · 2026. 9. 3. 업데이트됨 · NCT07175285A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
- Northwestern Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago
피험자 모집 중1상
18세 ~ 70세 · 모든 성별 · 2026. 8. 28. 업데이트됨 · NCT06925542RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
- Northwestern Memorial Hospital, Chicago
- The University of Chicago Medical Center, Chicago
피험자 모집 중1/2상
18세 ~ 65세 · 모든 성별 · 2026. 8. 26. 업데이트됨 · NCT06121297A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE), Sjogren's Disease (SjD) and Rheumatoid Arthritis (RA)
- Advanced Quality Medical Research /ID# 278462, Orland Park
피험자 모집 중1상
18세 ~ 75세 · 모든 성별 · 2026. 8. 10. 업데이트됨 · NCT06977724Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
- Robert A Hozman MD SC, Skokie
- Willow Rheumatology Wellness, Willowbrook
피험자 모집 중3상
12세 ~ 100세 · 모든 성별 · 2026. 7. 8. 업데이트됨 · NCT06133972Lupus Landmark Study: A Prospective Registry and Biorepository
- University of Chicago, Chicago
피험자 모집 중관찰 연구
18세 ~ 110세 · 모든 성별 · 2026. 4. 15. 업데이트됨 · NCT05934149ClinicalTrials.gov 출처, 2026. 9. 30. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.